Lowering Cutoffs for Initial and Confirmation Testing for Cocaine and Marijuana: Large-Scale Study of Effects on the Rates of Drug-Positive Results (Drug Monitoring and Toxicology) Lowering Cutoffs for Initial and Confirmation Testing for Cocaine and Marijuana: Large-Scale Study of Effects on the Rates of Drug-Positive Results (Drug Monitoring and Toxicology)

Lowering Cutoffs for Initial and Confirmation Testing for Cocaine and Marijuana: Large-Scale Study of Effects on the Rates of Drug-Positive Results (Drug Monitoring and Toxicology‪)‬

Clinical Chemistry 1997, Jan, 43, 1

    • $5.99
    • $5.99

Publisher Description

Five drug classes are monitored by the Substance Abuse and Mental Health Services Administration (SAMHSA), the federally regulated, civilian drug-testing program: cocaine (COC), marijuana (THC), amphetamines, phencyclidine, and opiates. (1) COC and THC are of primary interest because of their relatively high incidence, which is the result almost exclusively of abuse, their medical use being extremely limited. For the first 4 years after the inception of the SAMHSA drug-testing program, the initial testing (screening) and confirmation testing cutoffs for THC were 100 [micro]g/L and 15 [micro]g/L, respectively [1]; on September 1, 1994, the initial testing cutoff for cannabinoids was decreased to 50 [micro]g/L [2]. The initial testing and confirmation SAMHSA cutoffs for COC have remained at 300 [micro]g/L and 150 [micro]g/L, respectively. None of the other major civilian drug-testing programs such as the College of American Pathologists or New York State have mandatory reporting cutoffs for the urine drug-testing laboratories enrolled in their programs. The Department of Defense drug-testing program uses respective initial and confirmation test cutoffs of 50 and 15 [micro]g/L for THC and of 150 and 100 [micro]g/L for COC. The present study was undertaken to determine what cutoffs are obtainable with the methodologies now in use for COC and THC and whether applying lower cutoffs would lead to a significant increase in the rates of positive results found. Materials and Methods

GENRE
Science & Nature
RELEASED
1997
1 January
LANGUAGE
EN
English
LENGTH
11
Pages
PUBLISHER
American Association for Clinical Chemistry, Inc.
SELLER
The Gale Group, Inc., a Delaware corporation and an affiliate of Cengage Learning, Inc.
SIZE
210.9
KB
Interference with Testing for Lysergic Acid Diethylamide (Drug Monitoring and Toxicology) Interference with Testing for Lysergic Acid Diethylamide (Drug Monitoring and Toxicology)
1997
Dried Blood Spots Dried Blood Spots
2014
Analytical Chemistry for Assessing Medication Adherence Analytical Chemistry for Assessing Medication Adherence
2016
Use of On-Site Testing for Drugs of Abuse. Use of On-Site Testing for Drugs of Abuse.
2002
Evaluation and Performance Characteristics of the STA-R Coagulation Analyzer (Technical Briefs) Evaluation and Performance Characteristics of the STA-R Coagulation Analyzer (Technical Briefs)
2002
Specification of Drug Substances and Products Specification of Drug Substances and Products
2013
D-Dimer Testing for Deep Venous Thrombosis: A Metaanalysis (Clinical Report) D-Dimer Testing for Deep Venous Thrombosis: A Metaanalysis (Clinical Report)
2004
Congenital Analbuminemia Attributable to Compound Heterozygosity for Novel Mutations in the Albumin Gene (Technical Briefs) Congenital Analbuminemia Attributable to Compound Heterozygosity for Novel Mutations in the Albumin Gene (Technical Briefs)
2005
Highly Sensitive Immunoprecipitation Method for Extracting and Concentrating Low-Abundance Proteins from Human Serum (Technical Briefs) Highly Sensitive Immunoprecipitation Method for Extracting and Concentrating Low-Abundance Proteins from Human Serum (Technical Briefs)
2005
Measurement of Pro-C-Type Natriuretic Peptide in Plasma (Technical Briefs) Measurement of Pro-C-Type Natriuretic Peptide in Plasma (Technical Briefs)
2005
Newborn Screening for Lysosomal Storage Disorders (Editorials) Newborn Screening for Lysosomal Storage Disorders (Editorials)
2005
Inadequate Attempts to Measure the Microheterogeneity of Transthyretin by Low-Resolution Mass Spectrometry (Letters) (Letter to the Editor) Inadequate Attempts to Measure the Microheterogeneity of Transthyretin by Low-Resolution Mass Spectrometry (Letters) (Letter to the Editor)
2005